Catalyst Brief

← Calendar

Readoutin 14d

Incyte Corporation — Povorcitinib

Phase 3 primary completion: A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa.

Date
Dec 2026
Type
Readout
Indication
Hidradenitis Suppurativa (HS)

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.